Strategic Advisory for Novel Therapeutics and Drug Delivery Innovation
Novel modalities are the fastest-growing and most operationally complex segment of biopharma in 2026. The cell and gene therapy market alone is projected to reach USD 35.7 billion by 2030, growing at a CAGR of 23.3%. Antibody-drug conjugates (ADCs) attracted over USD 20 billion in M&A investment in 2025. RNA-based therapeutics - including mRNA, siRNA, and antisense oligonucleotides - are projected to generate USD 28.5 billion in annual revenue by 2028. Combined, these novel modality categories attracted over USD 50 billion in biopharma M&A investment in 2025 alone.
The science is advancing faster than most organizations can build the commercial, regulatory, and manufacturing infrastructure to support it. Novel therapies can require specialized manufacturing facilities, cryogenic supply chains, and site-of-care delivery models that conventional pharma infrastructure cannot support. ADCs require highly potent API manufacturing with specialized containment capabilities. RNA therapeutics require lipid nanoparticle formulation expertise that remains concentrated in a small number of CDMOs globally. The FDA issued 14 novel guidance documents on advanced therapy manufacturing in 2025 alone - reflecting how rapidly the regulatory framework is evolving.
Katogen advises companies developing novel therapies and innovative drug delivery platforms - drawing on 35+ years of operator experience across multiple modalities and therapeutic areas. We understand the operational complexity of novel modalities from the inside - not as observers, but as operators who have built and scaled multiple biopharma organizations.
What We Do
Modality Strategy and Portfolio Positioning
We help leadership teams build a clear strategic rationale for their modality choice — and position that rationale compellingly for investors, acquirers, and partners who need to understand why this platform, why now, and why your team.
Commercial Readiness for Novel Therapeutics
Launching a novel modality is not like launching a conventional drug. Payer education, site-of-care strategy, patient identification, and specialist engagement all require approaches that are specific to the modality. We help companies build commercial strategies that reflect that reality.
Regulatory Pathway Navigation
Novel therapies operate under evolving FDA guidance frameworks. We help companies identify the right regulatory pathway, anticipate the questions regulators will ask, and build the evidence package needed to support approval.
Manufacturing and CMC Strategy
Novel therapeutics can require specialized manufacturing infrastructure that most CDMOs are still building. We help companies identify the right manufacturing partners, negotiate CDMO relationships, and build CMC strategies that will survive acquisition diligence.
Drug Delivery Innovation Strategy
For companies developing novel drug delivery platforms — including extended-release, targeted delivery, and next-generation formulation technologies — we provide strategic advisory on platform positioning, IP strategy, partnership development, and commercialization planning.
Built for the Operator's Seat
Who This Is For?
CEOs and executive teams at biopharma and biotech companies developing novel therapeutics, or innovative drug delivery platforms — at any stage from early development through pre-commercialization.
Why Katogen?
We have built and scaled biopharma organizations across multiple modalities and therapeutic areas. We understand the operational complexity of novel modalities from the inside — not as observers, but as operators.
WORK WITH KATOGEN
If you are navigating a strategic inflection point — a capital raise, an acquisition, a turnaround, a regulatory challenge, or simply a moment where you need an experienced operator in your corner — we would welcome the conversation. Engagements are selective. The first step is a direct conversation to understand your situation and determine where Katogen can add the most value.
